The Economics of Genomics

Add to your list(s) Download to your calendar using vCal

• Dr Ed Wilson and Dr Brett Doble, Cambridge Centre for Health Services Research
• Tuesday 02 February 2016, 12:30-13:30
• CRUK Cambridge Institute room 009, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE.

If you have a question about this talk, please contact Dr James Hadfield.

Next up are Ed Wilson, Brett Doble from the . They are talking about how economic evaluation and assessment of New genomic tests and so-called individualised medicines have the capacity to improve patient outcomes, but incur added costs to the NHS . This is important because choosing to allocate the NHS ’s funds to treating one group of patients means they cannot be used to treat another: the more we spend on cancer therapies the less there is to spend on patients with other diseases. Economic evaluation attempts to estimate the added costs associated with a new treatment, and compare this with the added improvement in outcomes to determine whether the new treatment represents good value for money for taxpayers. In this seminar Ed & Brett will give a brief overview of the methods of economic evaluation, explaining their importance in ensuring the maximum benefit for the funds available. They will then show how these tools should be applied in the economic assessment of genomic medicine in oncology. Specific challenges are discussed and an example evaluating multiplex targeted sequencing for selecting targeted treatment in lung adenocarcinoma is presented.

Speaker Bios: Ed is a Senior Research Associate in Health Economics at the Cambridge Centre for Health Services Research, University of Cambridge. He trained in economics and then health economics at the University of York and holds a PhD in Health Economics from the University of East Anglia. He has expertise in decision analytic modelling, economic evaluation alongside clinical trials, option appraisal and programme budgeting and marginal analysis (PBMA). Ed has applied these in a variety of disease areas including obesity, stroke, dementia, lupus, IVF , erectile dysfunction, essential thrombocythaemia, diabetes, actinic keratosis, malignant melanoma, prostate cancer, cholecystitis, idiopathic pulmonary fibrosis and ulcerative colitis. His methodological research is in the area of efficient research design, specifically value of information analysis, a quantitative approach to setting research priorities making use of uncertainty in the results of economic evaluations to quantify the expected return on investment in further research.

Brett is a health economist, with international experience in academic research, consulting and the pharmaceutical industry. He received his BSc in Biochemistry and MSc in Clinical Epidemiology and Biostatistics from McMaster University in Canada where he was a Canadian Institutes of Health Research Strategic Training Fellow for Drug Safety and Effectiveness. He is currently completing his PhD at the Centre for Health Economics, Monash University in Australia where he was the recipient of the Donald Cochrane Research Scholarship. Recently, Brett also worked with the Garvan Institute of Medical Research in Australia on consulting projects assessing the economic impacts of population-wide whole genome sequencing. He has an expertise in the economics of genomic medicine and a particular interest in its applications in oncology and monogenic diseases. He has completed a number of economic evaluations of health technologies using decision analytic modelling and has an interest in further undertaking trial-based economic evaluations and developing economic methods for the assessment of diagnostic tests within the genomics context. Brett also has an interest in health outcomes research, specifically the use of ‘mapping’ to generate health state utility values.

This talk is part of the CRUK-CI Genomics Core seminar series series.

This talk is included in these lists:

• CRUK Cambridge Institute room 009, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
• CRUK-CI Genomics Core seminar series

Note that ex-directory lists are not shown.